{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:08:19Z","timestamp":1780495699073,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.msard.2025.106599","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T07:10:27Z","timestamp":1751008227000},"page":"106599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discontinuation of disease-modifying therapy in stable multiple sclerosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9236-0822","authenticated-orcid":false,"given":"Sufyan","family":"Shahid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6182-3551","authenticated-orcid":false,"given":"Ahmedyar","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9320-1228","authenticated-orcid":false,"given":"Minahil","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2153-1770","authenticated-orcid":false,"given":"Mishal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6509-2347","authenticated-orcid":false,"given":"Omama","family":"Ayatullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4696-5053","authenticated-orcid":false,"given":"Soban Ali","family":"Qasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6475-6352","authenticated-orcid":false,"given":"Ayesha","family":"Batool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.msard.2025.106599_bib0001","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.0000000000005345","article-title":"Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology."},{"issue":"15","key":"10.1016\/j.msard.2025.106599_bib0002","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s40265-023-01942-0","article-title":"Escalation versus induction\/high-efficacy treatment strategies for relapsing multiple sclerosis: which is best for patients?","volume":"83","author":"Edan","year":"2023","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.msard.2025.106599_bib0003","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing\u2013remitting multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.msard.2025.106599_bib0004","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.1007\/s00415-024-12584-x","article-title":"MS treatment de-escalation: review and commentary","volume":"271","author":"Selmaj","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106599_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578368","article-title":"As time goes by: treatment challenges in elderly people with multiple sclerosis","volume":"391","author":"Gelibter","year":"2024","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106599_bib0006","article-title":"Discontinuation of first-line disease-modifying therapy in patients with stable multiple sclerosis","author":"Coerver","year":"2024","journal-title":"JAMA Neurol. [Internet]"},{"issue":"7","key":"10.1016\/j.msard.2025.106599_bib0007","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial","volume":"22","author":"Corboy","year":"2023","journal-title":"Lancet Neurol. [Internet]"},{"issue":"5","key":"10.1016\/j.msard.2025.106599_bib0008","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamaneurol.2024.0395","article-title":"High-efficacy therapy discontinuation vs continuation in patients 50 years and older with nonactive MS","volume":"81","author":"Jouvenot","year":"2024","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106599_bib0009","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/1352458518765656","article-title":"Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60","volume":"25","author":"Hua","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106599_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2023.107612","article-title":"Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression","volume":"225","author":"Salavisa","year":"2023","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"12","key":"10.1016\/j.msard.2025.106599_bib0011","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1007\/s00415-020-10029-9","article-title":"Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease inactivity","volume":"267","author":"Kaminsky","year":"2020","journal-title":"J. Neurol. [Internet]"},{"issue":"10","key":"10.1016\/j.msard.2025.106599_bib0012","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/jnnp-2016-313760","article-title":"Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study","volume":"87","author":"Kister","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry [Internet]"},{"key":"10.1016\/j.msard.2025.106599_bib0013","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.msard.2019.07.021","article-title":"Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: effect on clinical and MRI outcomes","volume":"35","author":"Yano","year":"2019","journal-title":"Mult. Scler. Relat. Disord. [Internet]"},{"issue":"10","key":"10.1016\/j.msard.2025.106599_bib0014","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40263-023-01038-z","article-title":"Stopping disease-modifying treatments in multiple sclerosis: a systematic review and meta-analysis of real-world studies","volume":"37","author":"Prosperini","year":"2023","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.msard.2025.106599_bib0015","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","author":"Tramacere","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.msard.2025.106599_bib0016","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/13524585241303489","article-title":"DISCOntinuation of disease-modifying therapies in MS: the DISCOMS extension trial","volume":"31","author":"Corboy","year":"2025","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2025.106599_bib0017","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/brainsci12020215","article-title":"Safety of Fingolimod in patients with multiple sclerosis switched from Natalizumab: results from TRANSITION-A 2-year, multicenter, observational, cohort study","volume":"12","author":"Butzkueven","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.msard.2025.106599_bib0018","article-title":"Severe rebound disease activity after fingolimod withdrawal in a pregnant woman with multiple sclerosis managed with rituximab: a case study","volume":"25","author":"Caniba\u00f1o","year":"2019","journal-title":"Case Rep. Womens Health"},{"issue":"5","key":"10.1016\/j.msard.2025.106599_bib0019","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/brain\/awae409","article-title":"De-escalating and discontinuing disease-modifying therapies in multiple sclerosis","volume":"148","author":"Androdias","year":"2025","journal-title":"Brain"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:43:44Z","timestamp":1755650624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825003414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":19,"alternative-id":["S2211034825003414"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106599","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation of disease-modifying therapy in stable multiple sclerosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106599"}}